IP Group – executive interview

In this interview, IP Group CEO Greg Smith and Edison’s Dan Ridsdale discuss Edison’s view that the group offers a compelling asymmetric return profile through its exposure to potential future income streams from Pfizer’s anti-obesity products. Smith explains how IP Group has recognised a discounted value for these future licensing streams in NAV, reflecting clinical risk and contributing to a 13% increase in NAV per share to £1.10. He also covers progress towards the group’s target of £250m of cash realisations between 2025 and 2027, supported by exits including Hinge Health, Monolith and CoreWeave-related proceeds. Smith points to continued momentum in third-party capital through new mandates with abrdn and Australia’s CEFC, and he outlines IP Group’s AI exposure across enabling infrastructure, quantum, optical computing and healthcare applications, supported by a strong balance sheet and active capital returns.

The company has recently announced the appointment of Michael Queen, formerly CEO of 3i Group, as non-executive director and chair designate.

IP Group helps to create, build and support IP-based companies internationally. It focuses on companies that meaningfully contribute to regenerative (renewable), healthier (life sciences) and tech-enriched (deep tech) futures.